Opposing effects of androgen ablation on immune function in prostate cancer

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1220-1221

  Tang, Shuai ^a   Dubey, Purnima ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Androgen ablation; Castration resistant; CD8+ effector T cells; Prostate cancer; Tregs

Indexed keywords

ANTIANDROGEN; INTERLEUKIN 2;

ANDROGEN DEPRIVATION THERAPY; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; CASTRATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

EID: 84886944341     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20448     Document Type: Article

References (10)

1. Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98:14565-70; PMID:11734652; http://dx.doi.org/10.1073/pnas.251140998.
2. Drake CG, Doody AD, Mihalyo MA, Huang CT, Kelleher E, Ravi S, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005; 7:239-49; PMID:15766662; http://dx.doi.org/10.1016/j.ccr.2005.01.027.
3. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12:4957-71; PMID:17569623; http://dx.doi.org/10.2741/2441.
4. Ansar Ahmed S, Penhale WJ, Talal N. Sex hormones, immune responses and autoimmune diseases. Mechanisms of sex hormone action. Am J Pathol 1985; 121:531-51; PMID:3907369.
5. Akins EJ, Moore ML, Tang S, Willingham MC, Tooze JA, Dubey P. In situ vaccination combined with andro-gen ablation and regulatory T-cell depletion reduces castration-resistant tumor burden in prostate-specific pten knockout mice. Cancer Res 2010; 70:3473-82; PMID:20406970; http://dx.doi.org/10.1158/0008-5472.CAN-09-2490.
6. Tang S, Moore ML, Grayson JM, Dubey P. Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells. Cancer Res 2012; 72:1975-85; PMID:22374980; http://dx.doi.org/10.1158/0008-5472.CAN-11-2499.
7. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33:153-65; PMID:20732639; http://dx.doi.org/10.1016/j.immuni.2010.08.004.
8. McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. Proc Natl Acad Sci USA 2011; 108:7529-34; PMID:21502514; http://dx.doi.org/10.1073/pnas.1103782108.
9. Kastenmuller W, Gasteiger G, Subramanian N, Sparwasser T, Busch DH, Belkaid Y, et al. Regulatory T cells selectively control CD8+ T cell effector pool size via IL-2 restriction. J Immunol 2011; 187:3186-97; PMID:21849683; http://dx.doi.org/10.4049/jimmu-nol.1101649.
10. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-33; PMID:16308572; http://dx.doi.org/10.1172/JCI25947.